GeoVax Labs (NASDAQ:GOVX) Stock to Reverse Split on Wednesday, November 11th

Posted by Renee Jackson on Nov 10th, 2026

GeoVax Labs Inc. (NASDAQ:GOVX – Free Report) shares are set to reverse split on the morning of Wednesday, November 11th. The 1-24 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, November 10th.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX traded down $0.03 during midday trading on Tuesday, hitting $0.11. The company’s stock had a trading volume of 1,296,066 shares, compared to its average volume of 1,786,974. GeoVax Labs has a fifty-two week low of $0.11 and a fifty-two week high of $13.00. The stock has a market capitalization of $821,755.00, a price-to-earnings ratio of -0.01 and a beta of 3.85. The stock’s 50 day simple moving average is $0.32 and its 200 day simple moving average is $1.19.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. Noble Financial reissued an “outperform” rating on shares of GeoVax Labs in a research report on Tuesday, September 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $150.00.

Read Our Latest Stock Analysis on GOVX

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.